Rheumatoid arthritis (RA), 4 an autoimmune inflammatory disorder primarily of the diarthrodial joints, cripples about 1% of the global population and requires early therapeutic intervention for effective disease management. The clinical picture is characterized by extensive immune cell infiltration, inflammation of the synovial lining, and erosion of the cartilage and underlying bone. The pathogenesis of RA is complex with the involvement of numerous autocrine and paracrine cytokine loops that perpetuate and amplify the vicious cycle of chronic inflammatory pathways (1, 2) . Considering the complicated immunopathology of RA and the active involvement of cells of both the innate and adaptive arms of the immune system, inhibition of multiple pathways is highly desirable. Alternatively, identification and targeting of molecules crucially involved in the activation of both arms of the immune system could be an important approach.
Identified as a gene up-regulated during myeloid differentiation in response to IL-6 (3), MyD88 has over the years emerged as a canonical adaptor protein for the toll-like receptors (TLRs) and IL-1 family of receptors including IL-18R (4) . Moreover, with the participation of these receptors in the development of both innate and adaptive responses, the relevance of MyD88 as a key player and a promising therapeutic target for RA becomes enormous and demands extensive explorations.
MyD88 is a modular protein (5) that consists of a death domain at the N terminus (6) and a toll/IL-1 receptor (TIR) domain at the C terminus linked by an intermediate domain (5, 7) . The cross-talk between MyD88 and its interacting partners is mediated by the TIR domain located at their C termini (8) .
In the present study, we utilized the immunomodulatory property of a TIR domain-containing protein, TcpC, derived from uropathogenic Escherichia coli CFT073 (9) to study the role of MyD88 in the development of RA. TcpC bears a structural domain closely resembling the mammalian TIR domain in its C-terminal region. This domain aids TcpC in interacting with MyD88, thus preventing the association of MyD88 with its interacting partner (TLR or IL-1 receptor (IL-1R)), leading to abrogation of the signaling cascade (9 -11) .
We treated mice exhibiting collagen-induced arthritis (CIA) with TIR domain derived from TcpC (TIR-TcpC) and observed a significant remission of the disease activity. The disease-modifying effect of TIR-TcpC could be attributed to limitation of the pathogenic Th17 responses, which turned out to be an outcome of TIR-TcpC-induced inhibition of MyD88 signaling in dendritic cells (DCs) and CD4
ϩ T-cells. Abrogation of the MyD88 signaling cascade by TIR-TcpC arrested the activation of NFB and subsequent transcription of downstream Th17 signature ROR␥t in naïve CD4
ϩ T-cells cultured under Th17-polarizing conditions.
Our study further demonstrates the significance of MyD88 signaling in the development of RA through its effects on Th17 differentiation and function as observed in complete and cellspecific MyD88 Ϫ/Ϫ mice. Cumulatively, these results suggest a novel pathway for regulation of Th17 differentiation by MyD88 and also highlight the superiority of targeting MyD88 for effec-tive management of Th17 cell-mediated autoimmunities. Furthermore, we put forward TIR-TcpC as a novel and appealing therapeutic molecule for rheumatoid arthritis.
Experimental Procedures
Cloning, Expression, and Purification-Uropathogenic E. coli CFT073 strain procured from American Type Culture Collection (ATCC) was cultured and maintained according to the supplier's instructions. Genomic DNA was isolated using a commercially available kit (Qiagen), and the region of interest was amplified using the following gene-specific primers: TIRTcpC forward primer, 5Ј-AAGCTTTGTATGATTTTTTCATA-TCCCATGC-3Ј; TIR-TcpC reverse primer, 5Ј-AATTCT-TATCTTCTCCTGTATGCTATTTCAGCCAACTC-3Ј; TIR-RAR-TcpC reverse primer, 5Ј-AATTCTTATCTTGCCCTG-TATGCTATTTCAGC-3Ј. The forward primer for TIRRARTcpC was the same as for TIR-TcpC. All the primers were 5Ј-phosphorylated. The amplified products (TIR-TcpC and TIRRAR-TcpC amplicons) were cloned into pPAL7 expression vector (Bio-Rad) using a restriction endonuclease-free cloning strategy. The identity of recombinants obtained was verified by sequence analysis. Plasmids pPAL7-TIR-TcpC and pPAL7-TIRRAR-TcpC were amplified in E. coli DH5␣ and transformed into E. coli BL21(DE3) cells. Protein expression was induced using 1 mM isopropyl ␤-D-thiogalactopyranoside (Calbiochem) for 4 h at 37°C. The overexpressed protein was purified from inclusion bodies as follows. The inclusion bodies were harvested by centrifugation at 13,500 rpm for 60 min at 4°C. The inclusion bodies obtained were solubilized in 0.1 M sodium phosphate buffer, pH 7.0, containing 8 M urea at room temperature (shaking for 1 h). Thereafter solubilized protein was dialyzed against a urea gradient (stepwise) at 4°C. Refolded proteins TIR-TcpC and TIRRAR-TcpC with an 8-kDa N-terminal Profinity eXact tag (recognized by a mutant subtilisin protease, S189) were purified using Bio-Scale Mini Profinity eXact FPLC columns (Bio-Rad). Identity of the expressed protein was established by Western blotting using polyclonal serum raised against keyhole limpet hemocyanin-conjugated peptides derived from TcpC. Protein concentration was determined spectrophotometrically by measuring absorbance at 280 nm and calculated using the following equation: A 280 ϭ ⑀cl where ⑀ is molar extinction coefficient (liters/(mol ϫ cm)), A is absorbance at 280 nm, c is concentration (mol/liter), and l is the path length of the cuvette (cm). ⑀ for TIR-TcpC and TIRRARTcpC is 29,910 liters/(mol ϫ cm). The sequences corresponding to TIR-TcpC and TIRRAR-TcpC were subcloned into mammalian expression vector pEGFP-N1 (Clontech). The sequences of primers used were as follows: TIR-TcpC-EGFP forward primer, 5Ј-TCAAGCTTCGAATTCTGCCGCCACCAT-GTATGATTTTTTCATAT-3Ј; TIR-TcpC-EGFP reverse primer, 5Ј-GCGGTACCGTCGACTGTTATTATCTTCTC-CTGTATGC-3Ј; TIRRAR-TcpC-EGFP reverse primer, 5Ј-GCGGTACCGTCGACTGTTATTATCTTGCCCTGTA-TGC-3Ј. The forward primer for TIRRAR-TcpC-EGFP was the same as for TIR-TcpC-EGFP. The identity of recombinants was verified by sequence analysis.
Tissue Culture, Cell Lines, and Reagents-Cytokines IL-1␤, IL-2, IL-4, IL-6, IL-12, IL-23, TNF-␣, and TGF-␤ were purchased from R&D Systems and Peprotech. Cell line RAW-Blue was procured from Invivogen was cultured and maintained according to the suppliers' instructions. Tissue culture media Dulbecco's modified Eagle's medium, heat-inactivated fetal bovine serum (certified), and antibiotic-antimycotic solution were obtained from Gibco. Zeocin, Normocin, Quantiblue, and p65IP were purchased from Invivogen. Methyl-␤-cyclodextrin was obtained from Sigma.
Generation of Polyclonal Sera to TIR-TcpC-Antiserum was generated against TIR-TcpC by immunizing a rabbit (New Zealand White strain, 10 -12 weeks old, male) subcutaneously with 200 g of TIR-TcpC-derived peptides EQTLEVGDSLRRNIDL and FLNKKWTQYELDSLIC (Bioconcept) (sequences of the peptides were taken from a previous report (9)) conjugated to keyhole limpet hemocyanin (Sigma) and emulsified in complete Freund's adjuvant (Sigma). TIR-TcpC-derived peptides were coupled to keyhole limpet hemocyanin using the HOOK peptide coupling kit (GBiosciences). At day 14, a booster dosage of 150 g was given in incomplete Freund's adjuvant (Sigma). Subsequently, on day 23, a 5-10-ml bleed was taken and analyzed for reactivity by Western blotting.
Mice (12) . Briefly, mice were immunized intradermally with 100 g of chicken type II collagen (Chondrex) emulsified in complete Freund's adjuvant. Chicken type II collagen was dissolved in l0 mM acetic acid with mild stirring at 4°C. Each paw was scored individually for joint inflammation as described previously (13) on a scale of 0 -4. The scoring system used was as follows: 0, no evidence of erythema and swelling; l, mild erythema or swelling (detectable arthritis); 2, moderate erythema and swelling; 3, significant erythema and swelling encompassing entire paw; 4, maximal swelling with or without limb distortion. For radiographic analysis, at the end of the treatment period (ϳ6 weeks), animals were anesthetized, and fore-and hind paws were radiographed using In Vivo Imaging System FX Pro (Eastman Kodak Co.). The severity of bone erosion was ranked as described previously (13) using a modified version of the Larsen scoring method: 0, normal; 1, slight abnormality with any one or two of the exterior metatarsal bones showing slight bone erosion; 2, definite early abnormality with any of the metatarsal or tarsal bones showing bone erosion; 3, medium destructive abnormality with any of the metatarsal or any one of the tarsal bones showing definite bone erosion; 4, severe destructive abnormality with all the metatarsal bones showing definite bone erosion and at least one of the tarsometatarsal joints being completely eroded, leaving some bony joint outlines partly preserved; 5, mutilating abnormality with no bony outlines that can be deciphered.
Assessment of Serological Markers of Disease-Serum samples were collected and assayed for levels of cartilage oligomeric matrix protein (COMP), C-terminal telopeptides of collagen type II (CTX II), and matrix metalloproteinase (MMP)-3 in an ELISA-based assay. Kits for COMP, CTX II, and MMP-3 were purchased from AnaMar, Immunodiagnostics Systems, and R&D Systems. For the cytokine assay, the levels of various cytokines in serum or joint tissue homogenates were quantified using Ready-SET-Go! ELISA kits (eBioscience) following the manufacturer's instructions. Values observed were normalized to control (buffer).
T-cell Isolation, Transfection, Differentiation, and NFB Activity Estimation-Splenocytes harvested from C57BL6/J mice (4 -6 weeks old, male) were magnetically sorted for naïve CD4 ϩ CD62L ϩ T-cells (Miltenyi Biotech). Purified naïve CD4 ϩ T-cells were electroporated with 0.5 g of TIR-TcpC-EGFP or TIRRAR-TcpC-EGFP using an Amaxa Mouse T-cell Nucleofector kit (Lonza). Transfection efficiency was determined by FACS. Purified naïve T-cells were subjected to Th17 differentiation conditions as described previously (14, 15) . Briefly, purified naïve T-cells (0.5 million cells/ml) were treated with anti-CD3 (plate-bound, 1 g/ml; catalogue number 553057, BD Biosciences), anti-CD28 (1 g/ml; catalogue number 553294, BD Biosciences), TGF-␤ (5 ng/ml), IL-6 (40 ng/ml), IL-23 (50 ng/ml), anti-IL-4 (5 g/ml; catalogue number 554433, BD Biosciences), anti-IFN␥ (5 g/ml; catalogue number 554409, BD Biosciences), anti-IL-2 (10 g/ml; catalogue number 554375, BD Biosciences), IL-1␤ (10 ng/ml), and TNF-␣ (10 ng/ml). For intracellular staining, cells were stimulated with phorbol 12-myristate 13-acetate (Sigma) and ionomycin (Sigma) in the presence of GolgiStop (BD Biosciences) for 4 h prior to staining.
To determine levels of NFB activity in treated or untreated naïve CD4 ϩ T-cells, nuclear fractions were isolated using a Nuclear Extraction kit (Active Motif). NFB activity was estimated using a TransAM p65 kit (Active Motif). NFB activity was estimated in RAW-Blue cells according to the supplier's instructions.
Proliferation Assay-To determine proliferative activity, splenocyte cultures at the end of 48 h were pulsed with Co-immunoprecipitation Assay-100 g of TIR-TcpC carrying an N-terminal affinity tag (Profinity eXact tag) was incubated overnight at 4°C with agarose coupled to a mutant subtilisin protease, S189, that binds with high specificity to the Profinity eXact tag. The resin bound to TIR-TcpC was washed twice with 0.1 M phosphate buffer (pH 7.2). Then lysates of naïve CD4
ϩ CD62L ϩ T-cells stimulated with IL-1␤ for 90 min were incubated with agarose-bound TIR-TcpC for 1 h at 4°C followed by 30 min at 22°C. Nonspecifically bound proteins were removed by washing five times with wash buffer (0.1 M phosphate buffer, pH 7.2, 0.1% Nonidet P-40, 1ϫ protease inhibitor mixture (Sigma)). Lysates were prepared using nondenaturing Nonidet P-40 buffer (20 mM Tris HCl, pH 8, 137 mM NaCl, 1% Nonidet P-40, 2 mM EDTA) supplemented with 0.125% (w/v) N-octyl glucoside. Bound proteins were recovered from the agarose beads by boiling them in 2ϫ SDS loading buffer followed by 10% SDS-PAGE and Western blotting.
Western Blotting-Protein samples electrophoresed on a 10% SDS-polyacrylamide gel were transferred onto nitrocellulose membrane using a semidry Trans-Blot system (Bio-Rad). The blots were blocked with 5% bovine serum albumin (BSA) for 1 h at room temperature and then incubated with anti-MyD88 (1:2500; catalogue number 4283, Cell Signaling Technology) and anti-IL-1RI (1:2000; Ab8154, Abcam) antibody overnight at 4°C. Blots were then washed thrice using 1ϫ TBST (1ϫ Tris-buffered saline, pH 7.6, 0.1% Tween 20). Secondary antibody (anti-rabbit IgG-HRP (1:16,000; catalogue number 7074, Cell Signaling Technology) or anti-rat IgG-HRP (1:10,000; catalogue number 7077, Cell Signaling Technology)) was then added, and blots were incubated for 50 min at room temperature. Following three washes with TBST, blots were visualized using enhanced chemiluminescence reagent (Clarity ECL Western blotting substrate, Bio-Rad).
Cellular Uptake Assay of TIR-TcpC-For the in vivo cellular uptake assay, C57BL6/J mice (4 weeks old, male) were injected intravenously with FITC-conjugated BSA (FITC-BSA) or TIRTcpC (FITC-TIR-TcpC) (5 mg/kg of body weight). Four hours later splenocytes were examined by flow cytometry for the FITC-positive population among dendritic cells (DCs) or T-cells (CD4 ϩ ) using PE-anti-CD11c (1:100) and Alexa Fluor 700-anti-CD4 (1:100) antibodies.
For the in vitro assay, CD11c ϩ dendritic cells or naïve CD4 ϩ CD62L ϩ T-cells derived magnetically from spleen of C57BL6/J mice (4 weeks old, male, 0.1 million cells) were plated in poly-L-lysine-coated cell culture slides and treated with FITC-BSA, FITC-TIRRAR-TcpC, or FITC-TIR-TcpC (0.1 mg/ml) for 90 min. Cells were then washed, fixed with 4% paraformaldehyde, and mounted in Fluoroshield DAPI (Sigma), and images were acquired in a confocal microscope (LSM510 Meta).
Statistical Analysis-Multiple or binary comparisons were analyzed using analysis of variance (single factor) and Student's t test (unpaired, two-tailed), respectively. Differences in mean values were considered significant when p was Ͻ0.05.
Results

Uropathogenic E. coli-derived TIR-TcpC Ameliorates Collagen-induced
Arthritis-TIR homologous domain (residues 1-137) of TcpC, an immunomodulatory protein secreted by uropathogenic E. coli CFT073 (9), was expressed recombinantly in a bacterial system (supplemental Fig. S1, A-F) . Recombinant TIR-TcpC was analyzed for its biological activity in RAW-Blue cells, a mouse macrophage cell line that harbors an NFB-inducible secreted embryonic alkaline phosphatase reporter construct. The treatment with TIR-TcpC inhibited lipopolysaccharide (TLR-4 ligand)-driven NFB activation in a dosage-dependent manner with more than 50% reduction at a concentration of 2 M. Surprisingly, the inhibitory potential of TIR-TcpC was several times greater than that of p65IP (commercially available positive control) (supplemental Fig. S2 ).To analyze the therapeutic effect of TIR-TcpC, autoimmune arthritis with characteristics similar to RA was induced in C57BL6/J mice by immunization with heterologous chicken type II collagen (CII). Nearly 70% of mice immunized with CII displayed joint inflammation on day 28 postimmunization. Upon clinical onset of the disease, mice were randomized into two experimental groups, viz. disease control and TIR-TcpC, and treated with vehicle or TIR-TcpC, respectively, for 2 weeks. An approximate 50% reduction in joint inflammation was readily evident (Fig. 1A and Table 1 ). Also, radiographs acquired at the end of the treatment period distinctly showed the absence of early signs of joint erosion in TIR-TcpC-treated animals (modified Larsen score ϭ 0) that had begun in disease control mice (modified Larsen score ϭ 1). Apart from integrity of joint surfaces, radiographs also revealed a drastic decrease in soft tissue volume (translucent regions around bones that essentially signify inflammatory edema) (Fig. 1B ). An assessment of the serum biomarkers implicated in various disease processes such as inflammation, cartilage damage, and bone erosion was also carried out. The levels of proinflammatory cytokines such as IL-1␤, TNF-␣, and IL-6 were significantly reduced (Fig. 1,  C-E) . These proinflammatory cytokines are known to induce the release of soluble inflammatory mediators such as prostaglandins and leukotrienes. Furthermore, the levels of COMP, a component of the articular cartilage, and fragments of CII (CTX II), which are released into the circulation upon degradative action of MMPs, were found to be significantly low (Fig. 1,  F and H) . Low levels of COMP and CTX II were additionally a reflection of reduced activity of MMP-3 in line with its observed serum levels (Fig. 1G) . The reduced levels of COMP, CTX II, and MMP-3 primarily indicated architectural conservation of the cartilaginous tissue, hence the protective effect of TIRTcpC treatment. This was also an indication that the synovial lining in TIR-TcpC-treated mice had not been transformed into pannus, a hyperplastic aggressive tissue that is a rich source of matrix-degrading enzymes and cytokines. In another scenario, i.e. co-treatment, CII-immunized animals were treated with TIR-TcpC from days 0 to 14 postimmunization. In comparison with treatment, the mean arthritic score in both the experimental groups was lower, which essentially reflects disease-free survival in 25-30% of mice immunized with CII. In the co-treatment experiment, the severity of the arthritic score was found to be reduced by 70% in mice injected with TIRTcpC. In addition to a reduction in disease severity, clinical onset of disease was delayed by ϳ1 week (Fig. 1, I and J, and Table 1) .
TIR-TcpC Treatment Impaired CD4 ϩ T-cell Effector Functions-As CIA is a Th17 cell-mediated pathology (16), we examined the splenocytes of treated mice for various CD4 ϩ T-cell subsets. To study the impact of TIR-TcpC treatment on effector T-cell functions, C57BL6/J mice were immunized with CII and on clinical onset of the disease were treated with TIRTcpC. At the end of the treatment period (2 weeks), splenocytes were analyzed by flow cytometry for various CD4 ϩ T-cell phenotypes such as Th1 (CD4
, and Treg (CD4 ϩ FoxP3 ϩ ). A significant reduction was noted in the proportion of Th1 and Th17 cells, whereas the proportions of other phenotypes remained unaltered (Fig.  2A) . The findings of flow cytometric analysis were corroborated by the near-normal levels of IL-17A and IFN␥ in the joint tissue homogenates of treated mice vis-à-vis untreated controls (Fig. 2B) .
Besides analyzing the effect of TIR-TcpC treatment on effector T-cell phenotypes, splenocytes of treated mice were also analyzed for activation. T-cell activation was assessed using the activation marker CD69. Surprisingly, the frequencies of CD4 ϩ CD69 ϩ cells were comparable between TIR-TcpC treatment and control groups (Fig. 2A) . Taken together, TIR-TcpC (9) . To confirm the specificity of this interaction and hence the mechanism of action of TIR-TcpC, we performed pulldown assays in naïve CD4 ϩ T-cells. The cells were activated and prestimulated with IL-1␤ for 90 min to increase the intracellular expression of MyD88. The pulldown assays revealed a specific interaction between MyD88 and purified TIR-TcpC that was concentration-dependent (Fig. 3) . However, TIR-TcpC did not interact with type I IL-1 receptor, another member of the IL-1 signaling cascade. These results corroborate a previous report that highlighted interactions between the TIR domain of TcpC and MyD88 but not with other components of the TLR signaling pathway in RAW264.7 macrophages (9). Therefore, it was noteworthy to examine the effect of MyD88 deletion on the progression of CIA. For this, B6.MyD88 Ϫ/Ϫ mice or their wild type counterparts were immunized with CII and monitored for joint inflammation. Although CIA progressed normally in the control group (wild type), MyD88 Ϫ/Ϫ mice did not develop the disease at all (Fig. 4, A and B) . Furthermore, the frequency of Th1 and Th17 cells was negligible in splenocytes when analyzed using flow cytometry at the end of 4 weeks postimmunization with CII (Fig. 4, C and D) . Although the impact of TIR-TcpC treatment or MyD88 deletion on CD4 ϩ T-cell differentiation and consequently on autoimmunity is through macrophages/dendritic cells (antigen-presenting cells) as expected, it was still important to examine the relative contribution of CD4 ϩ T-cellor CD11c ϩ dendritic cell-specific MyD88 on CIA and in situ T-cell differentiation. Mice with specific MyD88 deletion in CD4 ϩ T-cells (MyD88⌬T) or CD11c ϩ dendritic cells (MyD88⌬M) were generated by crossing B6.MyD88 flox/flox with B6.CD4-cre or B6.CD11c-cre, respectively. MyD88⌬T, MyD88⌬M, or wild type mice were immunized with CII. Although the percent incidence and clinical onset remained comparable, the severity of CIA in MyD88⌬T or MyD88⌬M mice was noted to be 60 -65% lower than that of wild type controls (Fig. 4, A and B, and Table 1 ). Furthermore, flow cytometric analysis of splenocytes revealed a significant decrease in the frequency of Th17 cells in MyD88⌬T mice and MyD88⌬M mice, whereas relative proportions of Th1 cells were comparable between MyD88⌬T and wild type control (Fig. 4, C and D) .
Contrary to CD4
ϩ
T-cells, CD11c
ϩ dendritic cell-specific MyD88 deletion significantly down-modulated Th1 cell differ- ϩ CD62L ϩ T-cells (protein concentration, 50 g/ml) stimulated with IL-1␤ (10 ng/ml) were subjected to co-immunoprecipitation using the Profinity eXact-tagged TIR-TcpC (total protein, 0, 10, and 100 g) and S189-agarose bead system (described under "Experimental Procedures"). Proteins co-immunoprecipitated with TIR-TcpC were analyzed for the presence of MyD88 or IL-1RI by Western blotting. Total lysate loaded (Input) served as a control for expression of MyD88 and IL-1RI in the lysates. Data in the figure represent three independent experiments. entiation also (Fig. 4, C and D) . For ex situ analysis, CD4 ϩ CD62L ϩ naïve T-cells were isolated from MyD88 Ϫ/Ϫ or wild type mice and subjected to Th17 differentiation conditions. In line with in situ differentiation analysis, naïve T-cells derived from MyD88 Ϫ/Ϫ mice showed negligible differentiation into Th17 cells and were unresponsive to IL-1␤ treatment (Fig. 4, E and F) . To summarize, although MyD88 deletion limited to CD4 ϩ T-cells or CD11c ϩ dendritic cells significantly impairs Th17 cell differentiation, complete knockdown of MyD88 totally abrogates Th17 development and hence CIA.
TIR-TcpC Blocks IL-1␤-dependent Th17 Cell Differentiation-The impaired CD4
ϩ T-cell differentiation and autoimmunity, particularly in MyD88⌬T animals, prompted us to examine the direct effect of TIR-TcpC treatment on Th17 cell development. First of all the effect of proinflammatory cytokines, i.e. IL-1␤, IL-6, and TNF-␣, the levels of which were found to be down-modulated in treated joints, was studied on in vitro Th17 differentiation. As reported previously (15) , the presence of IL-1␤ in the differentiation milieu significantly enhanced Th17 cell differentiation, whereas TNF-␣ had no effect (Fig. 5, A and B) . The frequency of Th17 cells was negligible when IL-6 was not included in the differentiation mixture, signifying its indispensable role in Th17 cell differentiation (Fig. 5, A and B) . Surprisingly, TIR-TcpC treatment had an inhibitory effect only when IL-1␤ was included in the differentiation mixture (Fig. 5, A and B) . In conclusion, TIR-TcpC treatment blocked only the IL-1␤-mediated increase in Th17 cell differentiation.
The detrimental effect of TIR-TcpC treatment on IL-1␤-mediated Th17 cell differentiation was analyzed in further detail. Expression of IL-1RI is essential for IL-1 activity. Thus, naïve CD4 ϩ T-cells treated with IL-1␤ in the presence of TIR-TcpC were analyzed for surface expression of CD121a (IL-1RI). Flow cytometric analysis revealed no significant difference in the expression of IL-1RI (Fig. 5C ). This was also indicative of intact IL-6 signaling even in the presence of TIR-TcpC as the former is known to be a critical factor for IL-1RI up-regulation during polarization (15) . Furthermore, TIR-TcpC-treated naïve CD4 ϩ T-cells were noted to express lower levels of ROR␥t (master transcription factor involved in Th17 differentiation (17)) vis-à-vis the untreated control (Fig. 5C) . have shown internalization and subsequent blocking activity of TIR-TcpC to be My D88-dependent in uroepithelial cells and macrophages. Because endocytic uptake of protein antigens is relatively unknown in the case of helper T-cells, it was intriguing to explore the mechanism of its entry. A careful analysis of the TIR-TcpC sequence revealed the presence of three consecutive arginine residues (arginines 135-137) at the C terminus (supplemental Fig. S1G ). Numerous studies in the past have highlighted the remarkable property of cationic peptides especially polyarginine to penetrate cell membranes. We, therefore, hypothesized the arginine triplet (arginines 135-137) to mediate cell penetration of TIR-TcpC. To test this, we generated a variant of TIR-TcpC in which the arginine triplet (Arg-ArgArg) was mutated to Arg-Ala-Arg, designated as TIRRARTcpC, to see whether the consecutive triple arginine is necessary for internalization (supplemental Fig. S1G ). Spleenderived CD11c ϩ dendritic cells or CD4 ϩ CD62L ϩ naïve T-cells were treated with fluorescently labeled TIR-TcpC, TIRRARTcpC, or BSA (control) and analyzed by confocal microscopy. TIR-TcpC could readily be observed more or less evenly distributed in the cytosol of dendritic cells and naïve T-cells, whereas TIRRAR-TcpC could not enter the cytosol (Fig. 6A) . Furthermore, to study the uptake of TIR-TcpC in vivo, C57BL6/J mice (4 -6 weeks old, male) were injected with FITC-TIR-TcpC, and 4 h later CD11c
C-terminal Arg-Arg-Arg Motif Is Critical for Translocation across Cell
ϩ DCs and CD4 ϩ T-cells in spleen were analyzed for the FITC ϩ population by FACS. Significant proportions among DCs and T-cells were noted to be positive for FITC (Fig. 6B) . To analyze its impact on NFB activation, naïve CD4 ϩ
CD62L
ϩ T-cells were stimulated with IL-1␤ in the presence of TIR-TcpC or TIRRAR-TcpC. NFB activation was quantified as described under "Experimental Procedures." As expected, the IL-1/MyD88-mediated NFB activation was persistent in the presence of TIRRAR-TcpC, also suggesting its failure to translocate across the plasma membrane and subsequently prevent IL-1/MyD88 interaction through their TIR domains (Fig. 6C) . However, it was also important to see that the observed abrogation of activity is not an outcome of mutation-induced structural changes in TIR-RAR-TcpC. For this, the tyrosine fluorescence spectrum was recorded. TIR-TcpC and TIRRAR-TcpC showed exact spectral overlap, signifying minimal structural perturbations in TIR-RAR-TcpC (Fig. 6D) . Furthermore, TIR-TcpC and TIRRARTcpC sequences were cloned into a mammalian expression vector, electroporated into murine CD4 ϩ CD62L ϩ T-cells, and probed for their ability to block IL-1 signaling-dependent NFB activation. Both were found to be comparable in inhibiting NFB activation (Fig. 6E) . Thus, from these experiments, we concluded that the Arg-Arg-Arg motif is critical for its translocation through the cell membrane.
Several virulence factors, polycationic peptides (polyarginines), have been shown to be internalized into living cells via endocytosis and/or through lipid rafts (18) . To explore the role of lipid rafts and/or endocytosis in the entry of TIR-TcpC, naïve T-cells treated with methyl-␤-cyclodextrin (a cholesterol-extracting reagent that disrupts lipid rafts) were examined for IL-1␤-dependent activation of NFB. Methyl-␤-cyclodextrin prevented TIR-TcpC-mediated suppression of NFB activation (IL-1-driven) (Fig. 6F) .
TIR-TcpC Treatment Does Not Generate Neutralizing Immune Response-To determine whether TIR-TcpC treatment generates a neutralizing immune response, serum samples drawn at the end of the treatment period were analyzed for antibody titer. Also, splenocytes isolated at the end of the treatment period were examined for proliferative activity in response to TIR-TcpC stimulation. Both anti-TIR-TcpC titer and TIR-TcpC-specific proliferative response were noted to be close to untreated controls, whereas the proliferative response to CII stimulation was high (Fig. 7, A and B) .
Discussion
The present study utilized an immunomodulatory protein of bacterial origin, TIR-TcpC, known for active subversion of MyD88-dependent TLR signaling pathway, to underscore the functional relevance of MyD88 in the pathogenesis of rheumatoid arthritis (9, 11) . Surprisingly, TIR-TcpC was not only instrumental in delineating the precise contribution of MyD88 to RA pathology, but it also emerged as a promising therapeutic molecule targeting multiple pathways simultaneously. It drastically suppressed several aspects of arthritis in terms of inflammation, cartilage damage, and bone erosion. Although treatment with TIR-TcpC reduced the articular score by 50 -60%, it is likely that prolonged treatment or higher dosages would have further suppressed the inflammatory disease processes. As TIR-TcpC has been shown to be as effective as full-length protein, TIR-TcpC was used in our study (9) . Th17 cells, a subset of the CD4 ϩ helper T-cell lineage, have emerged as key contributors to the disease processes in RA as well as in CIA (19 -22) . In humans a strong correlation between systemic disease activity and the circulating levels of IL-17 and Th17 cells has been reported in RA patients wherein IL-17 promotes joint destruction and bone resorption; in CIA neutralization of IL-17 has been found to be protective against disease development, and its overexpression is associated with a spontaneous and more severe form of autoimmune arthritis (23) (24) (25) (26) (27) (28) (29) . Consistent with this, abrogation of Th17 responses by TIR-TcpC led to a significant limitation of the arthritic processes.
The observed defect in Th17 function induced by TIR-TcpC was determined to be an outcome of inhibition of various proinflammatory signaling cascades involving MyD88. Furthermore, TIR-TcpC affected the differentiation of Th17 cells in a drastic manner with modest effects on Th1 cells. This is in agreement with recent reports that highlight increased expres- sion of MyD88-dependent receptors IL-1R and TLRs on Th17 cells vis-à-vis Th1 cells (15, 30) . Moreover, these receptors are intricately involved in generation of Th17 cells in an indirect (31) as well as direct manner (15, 30, 32) . Acting in an indirect manner, these pathways activate innate immune cells, particularly antigen-presenting cells, which in turn potently stimulate adaptive immune responses (32) (33) (34) . On the other hand, evidence also suggests a direct action of MyD88-dependent (IL-1 and TLR) pathways on CD4 ϩ T-cells and promotion of their differentiation into Th17 cells (15, 30) . It is noteworthy that the MyD88-dependent IL-1 and TLR pathways are not only important for Th17 differentiation but also have a significant contribution in the onset and progression of RA through other mechanisms. Elevated levels of various TLRs such as TLR-2, -3, -4, and -7 and their ligands such as bacterial DNA, peptidoglycans, heat shock proteins, fibronectin fragments, etc. have been observed in rheumatoid synovium in RA patients; these in addition to viral infections are implicated in disease initiation and progression (35) (36) (37) (38) (39) (40) (41) (42) . Conversely, IL-1 is a well established therapeutic target in RA (43) (44) (45) . Elevated levels of IL-1, with a positive correlation with disease activity, have been detected in the plasma and synovial fluid of RA patients (46, 47) . In animal models, IL-1 appears to be the main contributor toward disease pathogenesis (13, 48 -50) .
Thus, TIR-TcpC targeted MyD88-dependent signaling in both innate and adaptive immune cells to provide a comprehensive inhibition of Th17 differentiation in vivo.
TIR-TcpC-induced inhibition of the IL-1/MyD88 pathway resulted in impairment of NFB activation, expression of ROR␥t, and subsequent Th17 differentiation, which is in line with a recent report that highlights the importance of p65 activity within CD4 ϩ T-cells for induction of optimal Th17 responses through the up-regulation of ROR␥t (51) . Notably, TIR-TcpC was added during early stages of lineage commitment, which indicated that early MyD88 signaling is essential for Th17 generation and is in agreement with recent reports that highlight the importance of IL-1 signaling during early stages of Th17 differentiation (15) . It could also be inferred that NFB activation during early stages of differentiation is important for optimal Th17 differentiation.
Although a few sporadic reports had pointed out an indirect involvement of MyD88 (based on the studies in mice deficient in MyD88-dependent TLRs) in the pathogenesis of RA, direct evidence and/or underlying mechanisms have so far remained elusive (52) (53) (54) . Addressing this ambiguity, the present study attempts to emphasize the unforeseen role of MyD88 as a valuable therapeutic target in RA. The absence of CIA in MyD88 Ϫ/Ϫ mice was a clear indicator of the absolute necessity of this molecule for the induction of arthritic processes. MyD88 deletion (complete or cell-specific) was associated with deficient or defective Th17 development both in vivo and in vitro. In the case of CD4 ϩ cell-specific MyD88 deletion, the defect could be the result of impaired IL-1-induced NFB activation during early stages of development as apparent from experiments with TIR-TcpC. However, this needs further investigation. Other possible explanations of the observed defect could be impaired IL-23R expression and inability of naïve CD4 ϩ T-cells to overcome Treg-mediated suppression as highlighted in studies by Chang et al. (14) and Schenten et al. (55) , respectively. The present study, therefore, brings into light the importance of targeting CD4 ϩ T-cell-specific MyD88 in controlling the differentiation of autoreactive Th17 cells and subsequently RA pathogenesis.
It could be argued that TIR-TcpC is less efficient than gene knock-outs. Several factors may account for the observed difference. For example, limited biological half-life may affect the complete blockade of MyD88 in target cells. Consequently, resurgence of proinflammatory responses during drug-free intervals between two consecutive dosages could also contribute to the limited in vivo efficacy of TIR-TcpC. It could also be a matter of timing of treatment as disease processes in arthritis are continuous. Hence, early, sustained, and prolonged treatment regimens are likely to be more effective at near-complete blockade of MyD88 signaling, which may require the use of suitable delivery vehicles such as osmotic pumps, nanoparticles, etc. and are beyond the scope of the present study. It is also likely that use of high initial dosages could result in an improvement in MyD88 blockade.
Interestingly, we did not find any compromise in the entry of TIR-TcpC into target cells as revealed through in vitro cellular internalization experiments in dendritic and CD4 ϩ T-cells. Furthermore, the interaction of TIR-TcpC was very specific for MyD88 as we did not find any interaction with IL-1R.
Notably, the inhibitory activity of TIR-TcpC was dependent on its cellular entry. TIR-TcpC crossed the plasma membrane through cholesterol-rich lipid rafts and its entry was similar to the internalization of arginine rich polycationic peptides which is in corroboration with a previously published report (9) .
Taking into account the central role of Th17 lymphocytes in RA, disruption of pathogenic processes leading to their generation is highly desirable. TIR-TcpC, herein, emerged as a potent anti-arthritic molecule capable of arresting disease processes in terms of initiation and progression in an effective manner, which it did so by controlling Th17 cell responses both in vivo and in vitro, through regulation of the common adaptor molecule MyD88.
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